SCHEMBL5565348

SCHEMBL5565348

C=C(C(=O)c1ccc(S(=O)(=O)NC(=O)C(C)C)cc1)c1cc(-c2cc3ccccc3[nH]2)c(OC)cc1OC.[NaH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX15 P16050 1/20 0.34
FLT1 P17948 1/20 0.33
FLT4 P35916 1/20 0.33
KDR P35968 1/20 0.33
SMO Q99835 2/20 0.33
CNR1 P21554 1/20 0.33
ADAMTS4 O75173 1/20 0.33
LMNA P02545 1/20 0.32
MMP2 P08253 1/20 0.32
MMP14 P50281 1/20 0.32
LARS1 Q9P2J5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560099 0.99 ALDH1A1 (0.40) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5564774 0.91 ALDH1A1 (0.41) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5559825 0.90 ALDH1A1 (0.42) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5566222 0.88 KDM4E (0.39) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5560109 0.87 KDM4E (0.40) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5566693 0.87 KDM4E (0.38) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5564766 0.86 KDM4E (0.39) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5559684 0.86 ALOX15 (0.42) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5565541 0.85 ALOX15 (0.41) ALDH1A1KDM4ENPSR1MEN1MAPT
SCHEMBL5565638 0.85 CA2 (0.47) ALDH1A1KDM4ENPSR1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 ALDH1A1 1653/4885KDM4E 2383/4885NPSR1 1840/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 ALDH1A1 1653/4885KDM4E 2383/4885NPSR1 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.